Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes

Diabetes, Obesity and Metabolism

Volumn 19, Issue 11, 2017, Pages 1635-1639

  Biester, Torben ^a   Aschemeier, Baerbel ^a   Fath, Maryam ^a   Frey, Marcel ^b   Scheerer, Markus F ^c   Kordonouri, Olga ^a   Danne, Thomas ^a  

^a Children's Hospital   (Germany)

^b ALCEDIS GMBH   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

dapagliflozin; diabetic ketoacidosis; HbA1c; hypoglycemia; insulin requirement; SGLT 2 inhibitor; type 1 diabetes

Indexed keywords

3 HYDROXYBUTYRIC ACID; DAPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE DURATION; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADULT; BLOOD; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; METABOLISM; PHASE 1 CLINICAL TRIAL; PILOT STUDY; URINE; YOUNG ADULT;

3-HYDROXYBUTYRIC ACID; ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; GLYCATED HEMOGLOBIN A; GLYCOSURIA; HUMANS; INSULIN; MALE; PILOT PROJECTS; YOUNG ADULT;

EID: 85021250357     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12975     Document Type: Article

References (20)

1. Campbell MS, Schatz DA, Chen V, et al. A contrast between children and adolescents with excellent and poor control: the T1D exchange clinic registry experience. Pediatr Diabetes. 2014;15:110-117.
2. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
3. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-2224.
4. Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581-590.
5. Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduced body weight as add-on therapy to metformin plus sulfonylurea. Diabetes Care. 2015;28:365-372.
6. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740-750.
7. Mathieu C, Herrera Marmolejo M, González González JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1134-1137.
8. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124-136.
9. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes. A randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412-419.
10. Tamez HE, Tamez AL, Garza LA, et al. Dapagliflozin as adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78.
11. Hürter P, Danne T. Diabetes bei Kindern und Jugendlichen. 6th Auflage ed. Springer-Verlag; 2005. S. 296f.
12. Blume H. Bioverfügbarkeit und Bioäquivalenz. In: Nürnberg E, Suhrmann P, eds. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Heidelberg, Germany: Springer-Verlag; 2011:1118-1133. Band 2: Methoden.
13. Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314:2241-2250.
14. Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480-1483.
15. Henry RR, Dandona P, Pettus J, et al. Dapagliflozin in patients with type 1 diabetes: a post-hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting beta-hydroxybutyrate levels from a phase IIa pilot study. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.12882.
16. Tirucherai GS, LaCreta F, Ismat FA, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. Diabetes Obes Metab. 2016;18:678-684.
17. Wiggam MI, O'Kane MJ, Harper R, et al. Treatment of diabetic ketoacidosis using normalization of blood 3-hydroxybutyrate concentration as the endpoint of emergency management. Diabetes Care. 1997;20:1347-1352.
18. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
19. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “Thrifty Substrate” hypothesis. Diabetes Care. 2016;39:1108-1114.
20. Mather KJ, Hutchins GD, Perry K, et al. Assessment of myocardial metabolic flexibility and work efficiency in human type 2 diabetes using 16-[18 F]fluoro-4-thiapalmitate, a novel PET fatty acid tracer. Am J Physiol Endocrinol Metab. 2016;310:E452-E460.